C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across…
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activity Robust in vivo tumor…
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid…
TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone MONTREAL, April 10, 2021 (GLOBE…
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical…
7 objective responses observed to date in multiple tumor types New responses reported in patients…
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage…
— Late-breaking presentation highlights preclinical data for AO-176 in T-ALL — BRISBANE, Calif., April 10,…
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of…
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies…